<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02534636</url>
  </required_header>
  <id_info>
    <org_study_id>IM011-002</org_study_id>
    <nct_id>NCT02534636</nct_id>
  </id_info>
  <brief_title>Safety Study of BMS-986165 in Healthy Subjects and to Treat Psoriasis</brief_title>
  <official_title>Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-986165 in Healthy Subjects and to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Efficacy of BMS-986165 in Subjects With Moderate to Severe Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish if BMS-986165 is safe and effective at treating
      autoimmune diseases. BMS-986165 which has shown some promise in preclinical studies for
      inhibiting autoimmune conditions. This study will be the first time this drug is given to
      humans, and will be conducted entirely in healthy subjects. It will be run in 4 Parts. Part A
      will investigate single oral doses of drug. Part B will investigate giving the drug daily for
      14 days. Part C will investigate daily doses for 14 days in healthy volunteers with Japanese
      decent. Part D will investigate whether food, stomach acidity or giving the drug in a capsule
      makes a difference to the safety and potential use of this drug.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>October 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">November 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of a single oral dose of BMS-986165 based on number of incidence of AE, SAEs, AEs leading to discontinuation or death, marked abnormalities in clinical laboratory tests, vital sign measurements, ECGs, telemetry, and physical examinations</measure>
    <time_frame>Approximately 3 months</time_frame>
    <description>Adverse Event (AE), Serious adverse event (SAE)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability of a single oral dose of BMS-986165 based on number of incidence of AE, SAEs, AEs leading to discontinuation or death, marked abnormalities in clinical laboratory tests, vital sign measurements, ECGs, telemetry, and physical examinations</measure>
    <time_frame>Approximately 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Safety of a multiple oral dose of BMS-986165 based on number of incidence of AE, SAEs, AEs leading to discontinuation or death, marked abnormalities in clinical laboratory tests, vital sign measurements, ECGs, telemetry, and physical examinations</measure>
    <time_frame>Approximately 3 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Tolerability of a multiple oral dose of BMS-986165 based on number of incidence of AE, SAEs, AEs leading to discontinuation or death, marked abnormalities in clinical laboratory tests, vital sign measurements, ECGs, telemetry, and physical examinations</measure>
    <time_frame>Approximately 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Effect of BMS-986165 on electrocardiographic (ECG) parameters such as heart rate in healthy subjects of any ethnic background (Parts A, B, C, D)</measure>
    <time_frame>Approximately 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of BMS-986165 on electrocardiographic (ECG) parameters such as PR interval in healthy subjects of any ethnic background (Parts A, B, C, D)</measure>
    <time_frame>Approximately 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of BMS-986165 on electrocardiographic (ECG) parameters such as QRS interval in healthy subjects of any ethnic background (Parts A, B, C, D)</measure>
    <time_frame>Approximately 3 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of BMS-986165 on electrocardiographic (ECG) parameters such as QTc interval in healthy subjects of any ethnic background (Parts A, B, C, D)</measure>
    <time_frame>Approximately 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">140</enrollment>
  <condition>Healthy Subjects</condition>
  <arm_group>
    <arm_group_label>Part A: Single ascending dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986165 or Placebo specified dose on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part B: Multiple ascending dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986165 or Placebo + Interferon alpha-2a recombinant specified dose on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part C: Multiple ascending dose</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986165 or Placebo specified dose on specified days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part D: Relative Bioavailability</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>BMS-986165 (Liquid) + BMS-986165 (Capsule) + Famotidine specified dose on specified days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-986165</intervention_name>
    <arm_group_label>Part A: Single ascending dose</arm_group_label>
    <arm_group_label>Part B: Multiple ascending dose</arm_group_label>
    <arm_group_label>Part C: Multiple ascending dose</arm_group_label>
    <arm_group_label>Part D: Relative Bioavailability</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Interferon alpha-2a recombinant</intervention_name>
    <arm_group_label>Part B: Multiple ascending dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Famotidine</intervention_name>
    <arm_group_label>Part D: Relative Bioavailability</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Part A: Single ascending dose</arm_group_label>
    <arm_group_label>Part B: Multiple ascending dose</arm_group_label>
    <arm_group_label>Part C: Multiple ascending dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding BMS clinical trial participation, please visit
        www.BMSStudyConnect.com

        Inclusion Criteria:

          -  Healthy Male and Female participants

          -  18 to 50 years of age (Parts A-D)

        Exclusion Criteria:

          -  Participants that had recent infections

          -  Participants with low blood pressure or increased heart rate

          -  Participants with any chronic health related problems

          -  Participants with active cancer within the last 5 years

          -  Participants with any other major medical illness
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://www.bms.com/studyconnect/Pages/home.aspx</url>
    <description>BMS clinical trial educational resource</description>
  </link>
  <link>
    <url>http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx</url>
    <description>Investigator Inquiry form</description>
  </link>
  <link>
    <url>http://www.fda.gov/MEDWATCH/safety.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>October 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 23, 2015</study_first_submitted>
  <study_first_submitted_qc>August 26, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 27, 2015</study_first_posted>
  <last_update_submitted>December 23, 2016</last_update_submitted>
  <last_update_submitted_qc>December 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 28, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Interferons</mesh_term>
    <mesh_term>Interferon-alpha</mesh_term>
    <mesh_term>Famotidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

